Results of the phase 3b/4 ANSWER study, recently published onlinein the Journal of the American Academy of Dermatology, show that concomitant use of Oracea Capsules and Soolantra Cream provided significant improvement in terms of percentage reduction in inflammatory lesions from baseline and the proportion of patients achieving 100 percent lesion clearance at week 12, compared to monotherapy with Soolantra Cream. Overall combination therapy was shown to improve treatment results in people with severe rosacea.
Publication of the complete data set follows the presentation of topline data from the ANSWER study in a poster session at the 2019 American Academy of Dermatology (AAD) Annual Meeting in March.
ANSWER is the first randomized clinical trial to compare the combination of Oracea® (doxycycline, USP) 40 mg Capsules (a modified-release capsule of doxycycline and the only approved oral treatment for inflammatory rosacea lesions) plus Soolantra® (ivermectin) Cream, 1% (indicated for the inflammatory lesions of rosacea) with Soolantra Cream administered as monotherapy. The data is consistent with the efficacy and safety seen in pivotal trials of Oracea Capsules and Soolantra Cream.